Kidney Cancer

High Body Mass Index May Predict Survival Outcomes in Renal Cell Carcinoma

High Body Mass Index May Predict Survival Outcomes in Renal Cell Carcinoma

By

The association between obesity, age, and renal cell carcinoma prognosis requires additional investigation.

Heading Toward Personalized Management of Advanced Kidney Cancer

Heading Toward Personalized Management of Advanced Kidney Cancer

By

The heterogeneity of kidney cancer makes each of the tumors unique and treatment decisions based on tumor characteristics especially challenging.

Nivolumab Plus Ipilimumab May Improve 2-Year Quality of Life in Advanced Renal Cell Carcinoma

Nivolumab Plus Ipilimumab May Improve 2-Year Quality of Life in Advanced Renal Cell Carcinoma

By

Findings previously demonstrated that nivolumab plus ipilimumab prolongs overall survival and was better tolerated among patients with renal cell carcinoma, but its impact on health-related quality of life was not reported.

Carmena Trial: Nephrectomy Plus Adjuvant Sunitinib vs Sunitinib Alone

Carmena Trial: Nephrectomy Plus Adjuvant Sunitinib vs Sunitinib Alone

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses the findings at the ASCO 2018 meeting.

Sunitinib May Eliminate the Need for Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma

Sunitinib May Eliminate the Need for Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma

By

The incorporation and efficacy of targeted therapies to management has called into question the conventional standard of using cytoreductive nephrectomy prior to sunitinib.

Pegilodecakin Plus Anti-PD-1 Agents May Be Effective in Metastatic Renal Cell Carcinoma

Pegilodecakin Plus Anti-PD-1 Agents May Be Effective in Metastatic Renal Cell Carcinoma

By

Researchers assigned 38 patients with metastatic renal cell carcinoma to receive pegilodecakin plus nivolumab or pembrolizumab.

Diabetes Ups Kidney Cancer Risk in Women

Diabetes Ups Kidney Cancer Risk in Women

By

Women with type 2 diabetes have a 1.5-fold higher risk of renal cell carcinoma compared with non-diabetic women.

Renal Cell Carcinoma:  How Biomarkers Could Affect Drug Development

Renal Cell Carcinoma: How Biomarkers Could Affect Drug Development

By

An example of where biomarkers may help to select the best medication for a patient and also assist in drug development is the tyrosine kinase inhibitor (TKI) dovitinib for renal cell carcinoma (RCC).

Cabozantinib Effective in Real-World Analysis for Relapsed Metastatic Renal Cell Carcinoma

Cabozantinib Effective in Real-World Analysis for Relapsed Metastatic Renal Cell Carcinoma

By

The phase 3 METEOR study previously demonstrated that cabozantinib significantly improved survival outcomes among patients with relapsed renal cell carcinoma.

No Single Gene Seems to Drive Renal Cell Carcinoma Metastasis

No Single Gene Seems to Drive Renal Cell Carcinoma Metastasis

By

Recent research indicates that there were no significant differences in the genomic landscape of clear cell RCC primary tumors and metastases, or between the different sites of metastases.

Does Sunitinib Have A Future in Renal Cell Carcinoma Treatment?

Does Sunitinib Have A Future in Renal Cell Carcinoma Treatment?

By

Immunotherapy may supplant sunitinib in RCC, except for in patients who cannot tolerate checkpoint inhibition.

FDA Approves Nivolumab With Ipilimumab for Renal Cell Carcinoma

FDA Approves Nivolumab With Ipilimumab for Renal Cell Carcinoma

By

Approval was based on results from the randomized phase 3 CheckMate-214 study.

Effects of A 2 Weeks on/1 Week Off Sunitinib Schedule in Metastatic RCC

Effects of A 2 Weeks on/1 Week Off Sunitinib Schedule in Metastatic RCC

By

The standard schedule is associated with AEs including grade 3 to 4 fatigue, HFS, and diarrhea.

Combinations: The Future of Renal Cell Carcinoma Treatment?

Combinations: The Future of Renal Cell Carcinoma Treatment?

By

Several phase 3 clinical trials are likely to identify new frontline standards of care.

Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma

Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma

By

Previous studies showed that combination therapy with nivolumab and ipilimumab has promising efficacy for various cancers, including RCC, compared with either agent alone.

Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma

Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma

By

VEGF and PD-1 pathway inhibitors show promising improvements compared with single-agent VEGF pathway inhibitors.

Renal Cell Carcinoma Treatment Regimens

Access a treatment regimen chart with detailed information for renal cell carcinoma, including tyrosine kinase inhibitors and cytokine therapy.

Axitinib With Avelumab Shows Promise as First-Line Therapy for Renal Cell Carcinoma

Axitinib With Avelumab Shows Promise as First-Line Therapy for Renal Cell Carcinoma

By

Researchers enrolled 6 and 49 patients into dose-finding and dose expansion stages, respectively.

PPI, H2RA Use With Pazopanib Does Not Affect PFS, OS in Renal Cell Carcinoma

PPI, H2RA Use With Pazopanib Does Not Affect PFS, OS in Renal Cell Carcinoma

By

Previous studies found that an elevated pH environment leads to nearly a 40% reduction in pazopanib exposure.

VHL and the Risk for Renal Cell Carcinoma — In the Clinic

VHL and the Risk for Renal Cell Carcinoma — In the Clinic

By

Close to 60% of all patients with VHL will develop RCC or renal cysts.

Multidisciplinary Models for Treating Renal Cell Carcinoma

Multidisciplinary Models for Treating Renal Cell Carcinoma

By

A shift toward multidisciplinary care is inevitable for the treatment of locally advanced and metastatic RCC.

Cabozantinib Superior to Sunitinib for First-Line RCC Treatment Across all Subgroups

Cabozantinib Superior to Sunitinib for First-Line RCC Treatment Across all Subgroups

By

Findings from the phase 2 CABOSUN study showed that, compared with sunitinib, cabozantinib improves PFS and the ORR among patients with advanced RCC.

Adjuvant Sunitinib Increases Mortality Risk Among Older Women With Renal Cell Cancer

Adjuvant Sunitinib Increases Mortality Risk Among Older Women With Renal Cell Cancer

By

Previous findings suggested that there were no benefits to overall survival or disease-free survival with VEGF-TKIs vs placebo.

Papillary Renal Cell Carcinomas May Respond to Crizotinib

Papillary Renal Cell Carcinomas May Respond to Crizotinib

By

Patients with PRCC1 frequently show MET mutations. Crizotinib, a dual inhibitor of MET and ALK, has shown promising activity in MET-altered cancers.

Antibiotics May Indirectly Improve PFS Among Patients With RCC Receiving TKIs

Antibiotics May Indirectly Improve PFS Among Patients With RCC Receiving TKIs

By

Patients receiving VEGF-TKIs are likely to have treatment dose reductions, delays, or interruptions because of diarrhea, which occurs in about 50% of cases.

Cabozantinib Yields Similar QoL Outcomes to Everolimus in Renal Cell Carcinoma

Cabozantinib Yields Similar QoL Outcomes to Everolimus in Renal Cell Carcinoma

By

The phase 3 METEOR trial demonstrated that cabozantinib prolonged PFS, OS, and ORR compared with everolimus, but the impact on QoL was not fully established.

Cabozantinib Improves OS, PFS, and ORR in Bone-metastatic RCC

Cabozantinib Improves OS, PFS, and ORR in Bone-metastatic RCC

By

The drug was, however, associated with a greater number of grade 3 to 4 adverse events.

Too Soon To Declare Whether Immunotherapy Can Cure Metastatic RCC

Too Soon To Declare Whether Immunotherapy Can Cure Metastatic RCC

By

Though uncommon, complete responses are seen among patients with metastatic disease, but CRs seem to occur more often with immune checkpoint inhibitors.

Cabozantinib Approved as First-line Therapy for Advanced Renal Cell Carcinoma

Cabozantinib Approved as First-line Therapy for Advanced Renal Cell Carcinoma

By

The FDA based its approval on data collected from the open-label, phase 2 CABOSUN study, for which researchers randomly assigned 157 patients with RCC to receive oral cabozantinib or sunitinib.

Non-steroidal Anti-inflammatory Drugs May Improve Survival in Kidney Cancer

Non-steroidal Anti-inflammatory Drugs May Improve Survival in Kidney Cancer

By

A cumulative-use analysis suggests that NSAIDs, ACEis, and SSRIs improve disease-specific outcomes among patients with kidney cancer, and further that NSAIDs improve overall survival.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs